While losartan + SOC did not significantly change the median survival compared to SOC alone (~40 days), SOC + anti-PD1 therapy and SOC + losartan + anti-PD1 led to 17% and 43% long-term survival (no detectable tumor at day 80). Here, UBXN11 is linked to neoplasm.